FDA's second review of dapagliflozin from Bristol-Myers Squibb Co. and AstraZeneca plc shows the agency is still on the hunt for any sign of potential CV risk for diabetes candidates - even when they clear the statistical hurdle outlined in 2008 guidance. The Endocrinologic and Metabolic Drugs Advisory Committee, however, appears to have swung back to center in its consideration of risk to benefit ratios.